<DOC>
	<DOCNO>NCT00962065</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy LX4211 versus placebo control subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Study LX4211 Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Males female ( nonchildbearing potential ) , age 1865 year Diagnosis Type 2 diabetes mellitus least 6 month prior screen Fasting plasma glucose ≤ 240 mg/dL prior metformin washout Body mass index &lt; 42 kg/m^2 HbA1c value 7 11 % Cpeptide ≥ 1.0 ng/mL Ability provide write informed consent History Type 1 diabetes mellitus , diabetic ketoacidosis , hyperosmolar nonketotic syndrome , incontinence , nocturia Use blood glucose lower agent metformin Prior exposure insulin , thiazide , loop diuretic within 4 week prior screen Laboratory electrocardiogram abnormality deem significant Sponsor Investigator Positive test result glutamic acid decarboxylase ( GAD ) antibody Surgery within 6 month screen Exposure investigational agent participation investigational trial within 30 day prior Day 1 Hypersensitivity SGLT2 inhibitor History drug alcohol abuse within last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>